Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1CG47)

• Drug Name: IL-2 XL Drug Info
• Synonyms: IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel

Indication

Disease Entry	ICD 11	Status	REF
Renal cell carcinoma	2C90	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DM1CG47

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-2 (IL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldesleukin	DM4YMIS	Acute myelogenous leukaemia	2A41	Approved	[3]
Daclizumab	DM6OZQV	Aplastic anemia	3A70	Approved	[4]
AIR-insulin	DM8SYTE	Diabetic complication	5A2Y	Phase 3	[5]
TG-4010	DMWE3GB	Bipolar disorder	6A60	Phase 2/3	[6]
BNZ-1	DM8JQZC	Cutaneous T-cell lymphoma	2B01	Phase 2	[7]
IL-2/CD40L-expressing leukemia vaccine	DMIHQ5G	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[8]
Carboxyamidotriazole orotate	DMN5JCX	Glioblastoma multiforme	2A00.0	Phase 2	[9]
Leuvectin	DM5LQEI	Melanoma	2C30	Phase 2	[10]
Human interleukin-2	DM0NJWG	Renal cell carcinoma	2C90	Phase 2	[11]
L19-IL-2 fusion protein	DMI2XP1	Lymphoma	2A80-2A86	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-2 (IL2)	TTF89GD	IL2_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020218)
• [2] Pharmacokinetics (PK) and immunologic responses in a phase I/II study of a sustained release formulation of IL-2 in renal cell carcinoma (RCC) patients. J Clin Oncol (Meeting Abstracts) June 2006 vol. 24 no. 18_suppl 2558.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [5] The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7.
• [6] A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
• [7] Clinical pipeline report, company report or official report of Bioniz Therapeutics.
• [8] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
• [9] J Clin Oncol 32:5s, 2014 (suppl; abstr 2071).
• [10] Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6.
• [11] Clinical pipeline report, company report or official report of Immunservice.
• [12] National Cancer Institute Drug Dictionary (drug id 665656).